Novartis compra un especialista en terapias contra el cáncer por 1.000 millones de dólares
Published: Thursday, May 2nd 2024, 14:10
Volver a Live Feed
The pharmaceutical giant Novartis has further expanded its pipeline in the field of nuclear medicine with an acquisition. The Basel-based company intends to transfer one billion US dollars to the US company Mariana Oncology, which specializes in cancer therapies, as an upfront payment. Up to 750 million could follow later in milestone payments.
Mariana Oncology is a biotechnology company focused on the development of novel radioligand therapies (RLTs) for the treatment of cancer, Novartis announced on Thursday. The acquisition strengthens Novartis' own RLT pipeline and expands its research infrastructure and clinical supply capabilities.
According to the industry portal Endpointnews, radiopharmaceuticals are part of a boom in oncology in which researchers are trying to target cancer-killing therapies to just the right cells. In this case, by delivering a radioactive compound to a tumor cell.
With the acquisition of Mariana Oncology, Novartis gains access to a broad portfolio of RLT programs. This includes the development candidate MC-339, which is being investigated in small cell lung cancer.
With Lutathera and Pluvicto, Novartis already has two approved RLTs. Only on Tuesday, the Group also announced that it was expanding its radiopharmaceutical research collaboration with PeptiDream.
©Keystone/SDA
Spanish 
English 
German 
French 
Arabic